Pharma & Biotech

Merck KGaA Partners with Inspirna to Advance Novel Therapy for RAS-mutated Colorectal Cancer

(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class…

2 years ago

Novo Nordisk Initiates Groundbreaking Collaborations for Innovative Obesity and MASH Treatments

(IN BRIEF) Novo Nordisk has announced separate research collaborations with Omega Therapeutics and Cellarity Inc. to explore innovative treatment approaches…

2 years ago

AstraZeneca Advances in Cell Therapy with Acquisition of Gracell Biotechnologies

(IN BRIEF) AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc. (NASDAQ: GRCL), a global biopharmaceutical company specializing…

2 years ago

Sanofi Ceases Development of Tusamitamab Ravtansine for NSCLC after Trial Misses Primary Endpoint

(IN BRIEF) Sanofi has announced the discontinuation of the global clinical development program for tusamitamab ravtansine, following an interim analysis…

2 years ago

Cancer Treatment Advances: FDA Recognizes Breakthrough Potential of BNT323/DB-1303 for Endometrial Cancer

(IN BRIEF) BioNTech and Duality Biologics have received Breakthrough Therapy designation from the FDA for their antibody-drug conjugate (ADC) candidate,…

2 years ago

Roche’s Xolair Nears FDA Approval for Reducing Allergic Reactions to Multiple Foods

(IN BRIEF) Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application…

2 years ago

Almirall S.A. to Participate in 42nd Annual J.P. Morgan Healthcare Conference

(IN BRIEF) Almirall S.A., a global pharmaceutical company specializing in medical dermatology, has confirmed its involvement in the 42nd Annual…

2 years ago

GSK’s Dostarlimab Shows Positive Results in Endometrial Cancer Trial

(IN BRIEF) GSK plc has announced positive results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, evaluating the use…

2 years ago